168 related articles for article (PubMed ID: 20881939)
1. Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease.
Reed BY; Masoumi A; Elhassan E; McFann K; Cadnapaphornchai MA; Maahs DM; Snell-Bergeon JK; Schrier RW
Kidney Int; 2011 Jan; 79(1):128-34. PubMed ID: 20881939
[TBL] [Abstract][Full Text] [Related]
2. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
Coban M; Inci A
Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
[TBL] [Abstract][Full Text] [Related]
3. Levels of Endocan, Angiopoietin-2, and Hypoxia-Inducible Factor-1a in Patients with Autosomal Dominant Polycystic Kidney Disease and Different Levels of Renal Function.
Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Lampropoulou I; Intzevidou E; Sioulis A; Balaskas E; Sarafidis PA
Am J Nephrol; 2018; 47(4):231-238. PubMed ID: 29597186
[TBL] [Abstract][Full Text] [Related]
4. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis in autosomal-dominant polycystic kidney disease.
Bello-Reuss E; Holubec K; Rajaraman S
Kidney Int; 2001 Jul; 60(1):37-45. PubMed ID: 11422734
[TBL] [Abstract][Full Text] [Related]
6. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
[TBL] [Abstract][Full Text] [Related]
7. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.
King BF; Torres VE; Brummer ME; Chapman AB; Bae KT; Glockner JF; Arya K; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
Kidney Int; 2003 Dec; 64(6):2214-21. PubMed ID: 14633145
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis and autosomal dominant polycystic kidney disease.
Huang JL; Woolf AS; Long DA
Pediatr Nephrol; 2013 Sep; 28(9):1749-55. PubMed ID: 22990303
[TBL] [Abstract][Full Text] [Related]
10. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
Irazabal MV; Torres VE; Hogan MC; Glockner J; King BF; Ofstie TG; Krasa HB; Ouyang J; Czerwiec FS
Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064
[TBL] [Abstract][Full Text] [Related]
11. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
Meijer E; Boertien WE; Nauta FL; Bakker SJ; van Oeveren W; Rook M; van der Jagt EJ; van Goor H; Peters DJ; Navis G; de Jong PE; Gansevoort RT
Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
[TBL] [Abstract][Full Text] [Related]
12. Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease.
Bae K; Park B; Sun H; Wang J; Tao C; Chapman AB; Torres VE; Grantham JJ; Mrug M; Bennett WM; Flessner MF; Landsittel DP; Bae KT;
Clin J Am Soc Nephrol; 2013 Jul; 8(7):1089-97. PubMed ID: 23520042
[TBL] [Abstract][Full Text] [Related]
13. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.
Cadnapaphornchai MA; George DM; McFann K; Wang W; Gitomer B; Strain JD; Schrier RW
Clin J Am Soc Nephrol; 2014 May; 9(5):889-96. PubMed ID: 24721893
[TBL] [Abstract][Full Text] [Related]
14. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease.
Zheng D; Wolfe M; Cowley BD; Wallace DP; Yamaguchi T; Grantham JJ
J Am Soc Nephrol; 2003 Oct; 14(10):2588-95. PubMed ID: 14514736
[TBL] [Abstract][Full Text] [Related]
15. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.
Park HC; Kang AY; Jang JY; Kim H; Han M; Oh KH; Kim SH; Noh JW; Cheong HI; Hwang YH; Ahn C
BMC Nephrol; 2015 Jun; 16():86. PubMed ID: 26092580
[TBL] [Abstract][Full Text] [Related]
16. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies.
Chapman AB
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1197-204. PubMed ID: 18579674
[TBL] [Abstract][Full Text] [Related]
17. Correlation of serum galectin-3 level with renal volume and function in adult polycystic kidney disease.
Ozkurt S; Dogan I; Ozcan O; Fidan N; Bozaci I; Yilmaz B; Bilgin M
Int Urol Nephrol; 2019 Jul; 51(7):1191-1197. PubMed ID: 31012038
[TBL] [Abstract][Full Text] [Related]
18. Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease.
Leierer J; Perco P; Hofer B; Eder S; Dzien A; Kerschbaum J; Rudnicki M; Mayer G
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206927
[TBL] [Abstract][Full Text] [Related]
19. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
[TBL] [Abstract][Full Text] [Related]
20. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)].
Nadar SK; Blann A; Beevers DG; Lip GY
J Intern Med; 2005 Oct; 258(4):336-43. PubMed ID: 16164572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
